Mereo BioPharma: setrusumab Phase 3 Orbit 2nd interim analysis mid-2025; alvelestat gets positive EMA orphan opinion

Mereo BioPharma Group plc

Phase 3 Orbit study of setrusumab in OI progressing to second interim analysis expected mid-2025; final analysis possible Q4 2025.
Alvelestat receives positive EMA COMP opinion for Orphan Designation; European Commission final decision expected Q1 2025.
Cash runway reaffirmed into 2027, funding through multiple key inflection points including setrusumab milestones.
Cosmic study in OI patients aged 2 to <7 years continuing; data will be evaluated with Orbit analyses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.